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CANCER MECHANISMS
Mechanisms of Oncogenic Cooperation
in Cancer Initiation and Metastasis
Laura G. Pedraza-Fariña
Department of Genetics, Yale University School of Medicine, New Haven, Connecticut
Cancer is a disease of extreme heterogeneity. Microarray analysis has identified thousands
of genes that are transcriptionally up- or down-regulated in tumor samples; molecularly char-
acterized lesions that play a causative role in tumorigenesis constitute more than 1 percent
of the human genome. Such a large number of “cancer genes” stirs the debate of whether
it is relevant to continue classifying cancer as a single condition. Yet, a discrete set of cellular
processes has been found to underlie such complexity. Their deregulation has been pro-
posed to act as a common denominator that enables tumors to evade cellular barriers to pro-
liferation and metastasis. Efforts have been made to identify and model the mechanistic
origins of cancer. Two such models are discussed here: the multistage model of cancer and
the cancer platform model. The former suggests cancer arises by the sequential acquisition
of mutations leading to the progressive erosion of normal cellular control mechanisms. In
contrast, the latter reduces cancer initiation to two interdependent conditions: sustained pro-
liferation with the concomitant inhibition of cell death. This review proposes that a third con-
dition — cellular differentiation — should be added to the cancer platform model.
Differentiation can act as a fail-safe mechanism against unrestrained cellular growth —
much like cell death. Clinical implications of the different models are also analyzed.
THE COMPLEXITY OF THE
CANCER PHENOTYPE
Cancer is an extremely heterogeneous
disease; tumors in different tissues display
strikingly different behaviors. For example,
tumors of the pancreas tend to be highly ag-
gressive, while prostate tumors are more
frequently organ-confined. Tumors that
arise in the same tissue can even exhibit an
array of cellular pathologies, ranging from
benign hyperplasias to highly invasive ma-
lignancies [1-3]. Cancer is also a complex
disease involving the deregulation of mul-
tiple signal transduction pathways. Since
the discovery of the first tumor-promoting
gene, hundreds of genes have been shown
to play a role in tumor initiation and pro-
gression, and research continues to uncover
many more. Microarray analysis has iden-
tified thousands of genes that are transcrip-
tionally upregulated or downregulated in
cancer samples [4-6]. It remains unclear
which transcriptionally deregulated genes
in an individual tumor play a causative role
in tumor initiation and maintenance and
which ones represent bystanders with no
selective advantage. Regardless of the role
specific genes may play in cancer progres-
sion, these studies underscore the fact that
by the time a tumor is histologically iden-
tified, it has accumulated a large number of
molecular lesions. In addition, a recent lit-
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identified 291 genes for which there are
molecularly characterized mutations and ev-
idence of a causative role in tumorigenesis.
These genes represent more than 1 percent
of the human genome [7]. Yet this number
is a conservative estimate, since the study
did not consider epigenetic regulation of
gene expression.The large number of muta-
tions found in tumor samples raises the
question of whether it is biologically mean-
ingful to classify cancer as a single disease
entity. Is there a common thread that under-
lies most, if not all, human malignancies?
Are there biological rules that govern cancer
initiation and progression?
Despite the heterogeneity observed in
cancer, most tumors share certain character-
istics: self-sufficiency in growth signals, in-
sensitivity to anti-growth signals, evasion of
apoptosis, acquisition of a limitless replica-
tive potential, sustained angiogenesis, and
tissue invasion and metastasis. These com-
mon traits, which have been termed “the
hallmarks of cancer,” allow tumors to breach
cellular barriers against expansion and
metastasis [8]. The similarity in the cellular
processes subverted in all cancer cells, re-
gardless of their tissue of origin, likely indi-
cates common tumor-initiation mechanisms
for the complex pathologies observed in
clinical tumor samples.
THE MULTI-STAGE MODEL
OF CANCER
Cellular transformation — the process
by which a normal cell is “transformed” into
a malignant one — is thought to take place
through the accumulation of mutations, as
well as epigenetic changes, that activate
oncogenes or downregulate tumor-suppres-
sor genes and lead to uncontrolled clonal ex-
pansion. Oncogenes originally were
identified as the transforming agents of
tumor viruses. It was later found that onco-
genes were mutated versions of normal cel-
lular genes, or proto-oncogenes, which had
been incorporated into the viral genome by
recombination. Mutations or epigenetic
events, leading to the deregulated activity or
increased expression of cellular oncogenes,
are found in most cancers. Oncogene activa-
tion is implicated in the positive control of
cellular growth, and mutations in oncogenes
are generally dominant. In contrast, tumor
suppressor genes function as negative regu-
lators of cellular growth. Mutations in
tumor-suppressors usually inactivate gene
function and are generally recessive. Thus,
inactivation of both copies of a tumor-sup-
pressor gene is usually necessary for tumor
development [9]. Efforts to define the mech-
anistic origins of cancer have focused on
identifying such genes, as well as the path-
ways they regulate.
Several lines of evidence indicate that
mutations in a single oncogene or tumor-
suppressor are insufficient to give rise to
cancer. First, most cancers develop late in
life and the incidence of disease increases
dramatically with age. Statistical analysis of
epidemiological data shows four to five rate-
limiting steps as necessary for cancer to
occur, implying that a cell needs to accumu-
late four to five sequential genetic lesions in
key regulatory pathways in order to become
malignant [10]. Second, in vitro experiments
using cell lines, as well as in vivo models of
cancer, confirm the multiple-hit hypothesis
for the majority of cancers, with retinoblas-
toma and certain types of leukemia being ex-
ceptions to the rule.
Initial research using transforming
retroviruses, which contained activated ver-
sions of normal growth-controlling genes,
indicated that alterations in a single gene
could lead to transformation of rodent cells
in culture [11-14]. However, the cells used
in these initial cancer studies were immortal
and could therefore proliferate indefinitely.
In addition, these cell lines most likely had
acquired a series of other genetic alterations
in culture.When these experiments were re-
peated with primary cell lines, it was found
that activation of at least one pair of onco-
genes was required for transformation. Re-
search by Land et al. [15] and Sinn et al.
[16], along with experiments carried out
with other sets of oncogenes, confirmed that
at least two cooperating mutations are re-
quired for cancer.
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classified as presenting with different
“grades,” which correspond to a set of phys-
iological markers (such as loss of differenti-
ation, abnormal ploidy, and morphology)
and correlate with patient outcome. Higher
grade tumors have a more negative progno-
sis, while low-grade tumors are often con-
sidered early lesions and may progress to
more invasive, high-grade disease. These
observations have led to the hypothesis that
cancer progression can be dissected into a
small number of crucial steps whose sequen-
tial deregulation is critical for the clinical
progression from low- to high-grade cancer.
Several pathways with key functions in nor-
mal cell biology are deregulated in tumors:
Cell cycle entry
Normal cells tightly regulate cell cycle
progression via a number of crucial proteins
that work at the cell-cycle checkpoints to in-
tegrate information from both the external
and internal cellular environments. One such
protein is the tumor-suppressor protein Rb.
In its hypo-phosphorylated state, Rb binds
to transcription factor E2F and prevents it
from activating cellular genes involved in
DNAreplication. When Rb becomes hyper-
phosphorylated, transcription factor E2F is
released, allowing for the transcription of
genes essential for DNA synthesis [17-19].
Alterations at any level of the cell cycle con-
trol hierarchy leading to the disruption of the
normal function of Rb can be found in most
cancers.
Cell growth arrest, apoptosis,
and senescence
Cellgrowtharrest,death,andsenescence
are essential mechanisms that not only regu-
latenormaldevelopmentbutalsopreventthe
accumulationofharmfulmutations. Proteins
that stimulate these processes are likely
downregulatedincancercellsduetoselective
pressure to proliferate incessantly. The ex-
pression of several pro-apoptotic proteins,
such as p53, has been found to be either re-
duced or eliminated in cancer cells [20].
In addition, cellular senescence, which
regulates normal cellular lifespan, is also
disrupted in cancer. Telomere length is
thought to play a crucial role in modulating
genomic stability and cellular lifespan.
Telomeres are repetitive sequences at the
ends of chromosomes that prevent them
from being recognized as products of DNA
fragmentation.Telomere length is shortened
with each DNAreplication until it reaches a
critical length below which the cell can no
longer divide and becomes senescent [21].
However, when cultured in vitro, a subset of
tumor cells was found to have acquired an
unlimited replicative lifespan. These cells
maintain stable telomere lengths through the
upregulation of the enzyme telomerase,
which extends telomeric DNA[22-24].
Growth factor signaling
Growth factors provide environmental
cues to regulate cell growth and prolifera-
tion. Growth-factor independence is one of
the hallmarks of cancer. Constitutive activa-
tion or elevated expression of membrane re-
ceptors, such as EGFR and PDGFR, as well
as non-receptor proteins that relay growth-
factor signaling, such as ras or myc, is pres-
ent in the majority of cancers [25-29].
Invasion and metastasis
Cancer cells have the ability not only to
grow in the tissue of origin, but also propa-
gateandcolonizedistantsites.Theprocesses
of invasion and metastasis have been com-
pared with the normal physiological
processes of embryonic cell migration and
wound healing. Several of the molecules re-
sponsible for these physiological processes
are deregulated in invasive malignancies.
Cancer cell migration is regulated by inte-
grins,matrix-degradingenzymes,andcell-to-
celladhesionandcommunicationmolecules.
In particular, the adhesion molecule E-cad-
herin has emerged as a key regulator of
metastasis initiation. Loss of E-cadherin ex-
pression in the primary tumor weakens ep-
ithelial cell-cell contacts and is thought to
allow the release of invasive cells [30].
Experimental evidence supports that the
pathwaysdescribedaboveplayakeyroleintu-
morigenesis.Mostnotably,invitromodelswith
humancellshavebeenabletoreconstitutecan-
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ations.Itwasfoundthatatleastfourpathways
must be altered in order for tumor progression
to occur: maintenance of telomere length
(achieved by expressing human telomerase),
deregulated cell-cycle entry (inactivation of
Rb),deregulatedcellgrowtharrestandapopto-
sis(inactivationofp53),andgrowth-factorin-
dependence(byoncogenicrasoverexpression)
[31] (Figure 1). It remains to be explored how
different oncogenes and tumor-suppressors
foundintumorsamplescontributetothesecan-
cer pathways and how they interact with each
othertoreinforcetheirtumorigenicpotential.
THE CANCER PLATFORM MODEL
The multi-stage model of cancer postu-
lates that a series of sequential events that
progressively bypass cellular growth-control
mechanisms are needed for tumorigenesis.
In contrast, the cancer platform model posits
that the principles governing cancer initia-
tion can be further reduced to two interde-
pendent conditions — stimulation of
proliferation with a simultaneous block of
cell death within a single cell. In this model,
proliferation and death pathways are linked
not only in tumor initiation, but also in nor-
mal development.
Early experiments with transforming
retroviruses showed overexpression or acti-
vation of oncogenes frequently led to
growth arrest or apoptosis. To date, most
oncogenes have been found to either sensi-
tize cells to cell death, directly cause cell
death, or promote growth arrest. For exam-
ple, activation of ras in rat embryo fibrob-
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B: Genetic pathways required for the
transformation of human cells.
Deregulation of four genetic path-
ways is sufficient to convert normal
human cells to cancer cells in vitro.
Expression of the SV40 protein large
T antigen antagonizes Rb and p53
function, thus allowing unrestrained
cell cycle entry and resistance to
apoptosis. Overexpression of telom-
erase maintains telomere length
while activated Ras (RasV12) con-
fers cells with growth-factor inde-
pendence.
Figure 1: The multistage model of cancer.
A: Schematic representation of the “Hallmarks of Cancer” proposed by Hanahan and
Weinberg. Cancer arises by the step-wise accumulation of mutations in key signal trans-
duction pathways that lead to the acquisition of a common set of capabilities. While all
cancers share a common set of properties, the particular combination of mutations that
allow unrestrained growth will be tumor-specific.lasts leads to growth arrest, while activation
of src and myc promotes cell death [32-34].
These observations suggest that uncon-
trolled cellular proliferation could trigger
these pathways as a means to control unre-
strained growth. However, proliferation and
death also are part of normal development,
and a high-proliferative rate is required for
certain developmental periods. Therefore, a
cell would have to be able to distinguish be-
tween a normal high proliferative rate and
the abnormal cell proliferation characteristic
of cancer cells in order to appropriately ac-
tivate cell death pathways in response to ex-
cessive cell growth.
During development, environmental
cues — most importantly, growth factor and
nutrient availability — determine whether a
cell is able to proliferate. Thus, it was pro-
posed that the activation of pathways lead-
ing to cellular growth stimulates both
proliferation and death; only when trophic
environmental factors that support growth
by blocking cell death are present is a cell
able to proliferate. The ability to stimulate
both proliferation and death has been recog-
nized for several oncogenes, including c-
myc, ras, e2f, v-jun, CDKs and cyclins.
Furthermore, it was found that in fibroblasts,
myc-induced apoptosis could be inhibited by
serum or IGF and that E2F induced high
rates of cell death in the absence of serum.
These results suggest environmental signals
are indeed crucial for oncogenic stimulation
of proliferation [35, 36]. The interdepend-
ence between proliferation and death could
represent an evolutionary response against
cancer progression.
According to the cancer platform
model, cancer is a rare occurrence due to the
low statistical probability of one cell gaining
two mutations simultaneously in a single,
rate-limiting step of cancer initiation. Once
a “cancer platform” of uncontrolled cellular
expansion is established, the interaction of
this expanding cellular mass with its envi-
ronment will give rise to subsequent muta-
tions that allow for other traits of
malignancies to develop: angiogenesis, im-
mune evasion, invasion, and metastasis. In
addition, since apoptosis is frequently trig-
gered in DNA-damage response pathways
to eliminate unwanted cells, blocking apop-
tosis can lead to an increase in mutation
rates. Finally, several of the characteristics
of cancer cells may reflect intrinsic proper-
ties of proliferating cells and expanding tis-
sues, rather than the accumulation of new
mutations, as well as properties of the cells
and/or tissue of origin. [37,38]. For example,
in comparison to more differentiated cells,
oncogenic mutations in a stem cell may give
rise to more malignant, undifferentiated can-
cers with self-renewal capacity (Figure 2).
Both models discussed above propose
that the complexity of the cancer phenotype
can be reduced to a small set of common
pathways that must be deregulated for can-
cer progression. The cancer platform model
identifies two processes of key importance
in tumorigenesis: cellular proliferation and
death.This has important therapeutic signif-
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Signals that induce cell prolifer-
ation simultaneously engage
the apoptosis machinery unless
pro-survival factors are present.
Oncogene activation and tumor-
suppressor loss stimulate prolif-
erative and apoptotic pathways
leading to a net loss of cells.
Cancer will arise only when a
cell sustains mutations that si-
multaneously promote prolifera-
tion while blocking cell death (or
providing survival factors) thus
providing a cancer platform.
Figure 2: The cancer platform model.icance since it implies that cancer cells could
be eliminated by targeting either the onco-
genic lesion that confers proliferative advan-
tage to the tumor cells or the apoptotic
pathways deregulated in these cells. Under-
standing the mechanisms of oncogenic stim-
ulation of proliferation and death is
important to dissect specific cancer-initia-
tion pathways and to develop therapeutics.
GENETIC PATHWAYS IN CANCER
Even though the same processes seem
to be deregulated in all cancer cells, tumors
arising in different cells or tissues may pref-
erentially deregulate specific pathways that
contribute to these processes. In addition,
specific oncogenes or tumor-suppressors
may be more frequently mutated or exhibit
altered expression in some tissues. It is pos-
sible there is a genetic signature in different
types of cancer determined both by the tis-
sue and cells of origin and by the oncogenic
and tumor-suppressive lesions it has under-
gone. Moreover, if deregulation of an onco-
gene activates a specific cell death pathway,
it is likely that tumors in which this onco-
gene is deregulated also successfully have
blocked that pathway. While mutations
occur at random, once the first (or first two)
lesions have been selected for and fixed in a
clonal population, the new mutations the
tumor acquires could be influenced by ex-
ternal environmental selection pressures as
well as internal selection pressures of the
mutations already selected.Thus, tumor ini-
tiating mutations may predict what types of
mutations may occur later in the life of a
tumor.
Colon cancer is one of the few malig-
nancies for which a genetic pathway has
beendefined.Colorectalcancersfollowade-
fined histological pattern of development
from adenomas to carcinomas; each of these
histological changes is accompanied by mu-
tationsinspecificgenesinalargepercentage
of tumors [39]. More recently, microarray
analysis has been used to generate expres-
sion-based classifications of different tumor
types. Most tumors show characteristic ex-
pression signatures recognizable both for in-
dividual tumors and for tumor families with
shared characteristics. Further, molecular
classification of tumors has revealed differ-
ent tumors show similarities that can be as-
cribed to the tissue or cell-type of origin. In
addition, tumors’ molecular signatures can
be grouped to predict clinical outcome. For
example, analysis of histologically indistin-
guishable breast cancer samples identified
four subgroups: ER+-luminal like, HER2+,
normal breast, and basal-like; of these four,
the last was a predictor of poor outcome.
These findings suggest there are subsets of
mutations that correlate with specific types
of cancer, as well as subsets of genes that
correlate with the degree of malignancy of
specific tumors [6,40].
The concept that there is a genetic sig-
nature to cancer is compatible with all of the
models discussed so far. In principle, it
would be possible to describe pathways for
tumors in different tissues and with different
cellular origins, which could predict out-
come and help design specific therapies.The
existence of genetic pathways may imply
that late-stage tumors are still dependent on
the original lesions for survival. Alterna-
tively, new mutations may not be influenced
by earlier ones. Once a specific process is
thwarted, as in the bypassing of barriers
against uncontrolled proliferation, new mu-
tations are selected independently of the
original mutations. If the first approach is
correct, understanding tumor-initiating
events in the context of different molecular
lesions will be crucial to develop effective
cancer therapies.
ONCOGENES AS THERAPEUTIC
AGENTS
If tumors remain dependent on their ini-
tial transforming oncogenic mutations for
growth and survival, oncogene inactivation
could lead to tumor regression, even in ma-
lignant cancers. This hypothesis has been
tested using inducible mouse models of can-
cer [41]. In particular, several studies evalu-
ating the overexpression of the myc
oncogene in lymphoid and epidermal tissues
showed that the inactivation of myc led to
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tant promotion of either differentiation or
apoptosis [42-45]. However, in other mod-
els, a fraction of tumor cells were found to
be refractory to myc inactivation; these cells
presumably had acquired new mutations that
allowed myc-independent growth [46-49],
suggesting that while mutations that give
rise to tumors are often interdependent, new
lesions also can arise independently of pre-
existing ones, often replacing their function.
Therefore, targeting tumor-initiating muta-
tions may not eliminate all tumor cells.
Metastasis represents the main cause of
treatment failure for cancer patients, since
even complete resection of the primary
tumor can leave behind undiscovered mi-
crometastases. The traditional model of
metastatic progression postulates that only a
small subset of cells from the primary tumor
have acquired the requisite mutations to
metastasize to distant sites, where new mu-
tations are accumulated as a response to the
different selective pressures of a novel envi-
ronment [50]. However, recent data suggest
that most cells in primary tumors with
metastatic potential already contain the le-
sions necessary for metastasis and, possibly,
for survival in a foreign environment. Mi-
croarray analysis compared patterns of gene
expression in lymph node-negative breast
cancer patients with their known five-year
survival and recurrence rates. Seventy genes
were identified that could predict clinical
outcome with a combined 83 percent accu-
racy [51]. In addition, it was found that solid
tumors of different origin shared the same
metastatic signature, implying there is a
common set of molecules regulating metas-
tasis in a variety of primary tumors [52,53].
If this model is correct, it follows that muta-
tions involved in tumor initiation also may
be predictive of clinical outcome.The ability
to identify and understand the molecular sig-
natures of metastatic and non-metastatic pri-
mary tumors would provide new prognostic
markers. In addition, if mutations that confer
metastatic potential are present in the pri-
mary tumor, and if metastatic lesions remain
dependent on the original oncogenic muta-
tions for their survival, targeting these genes
also may be an effective therapy against
metastatic spread. Delineation of the genetic
pathways involved in specific tumors will be
crucial for identifying these initial onco-
genic mutations.
OUTLOOK: DIFFERENTIATION
AS AN ELEMENT OF TUMOR
INITIATION
Different models of cancer initiation
have focused on deregulation of prolifera-
tion and cell death as the main engines of
cancer progression. However, impaired dif-
ferentiation is a characteristic of most can-
cers, as a decrease in the degree of
differentiation correlates with highly malig-
nant lesions. Several oncogenes have been
shown to regulate cell-fate decisions. Thus,
depending on the cellular context, onco-
genes can promote not only proliferation and
death, but also differentiation, which can act
as a failsafe mechanism against unrestrained
growth [54]. Expression of c-myc in bone
marrow cells leads to a loss of cell-renewal
activity in hematopoietic stem cells leading
to differentiation [55]; ras and src are highly
expressed in developing neurons and their
overexpression leads to neurite outgrowth in
PC12 cells [56-59]. In addition, oncogene
activation does not always lead to cell death
and may even protect against it. In these
cases, terminal differentiation could be an
effective mechanism to thwart tumor pro-
gression [60].
The dual cancer platform may not be
sufficient for cancer progression in all con-
texts, and a third axis may be needed: cellu-
lar differentiation. In this expanded model,
only when oncogene-induced differentiation
effectively is blocked by additional muta-
tions or when the cellular environment fos-
ters the proliferating function of the
oncogene will tumors arise. Promoting pro-
liferation while simultaneously preventing
differentiation thus may constitute in spe-
cific situations a sufficient platform for can-
cer expansion. In others, the simultaneous
blockade of apoptosis and differentiation, to-
gether with the promotion of proliferation,
may be needed to establish a cancer plat-
101 Pedraza-Fariña: Mechanisms of oncogenic cooperationform. Mutations that block cellular differen-
tiation likely will have oncogenic capabili-
ties in the context of molecular lesions that
deregulate proliferation and prevent cell
death. Identification of genes responsible for
cell-fate determination may thus provide
new insights into mechanisms of cancer ini-
tiation as well as provide novel targets for
cancer therapies.
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